Tonix Pharmaceuticals (NASDAQ:TNXP) Releases Earnings Results, Beats Estimates By $1.80 EPS

Tonix Pharmaceuticals (NASDAQ:TNXP) posted its quarterly earnings results on Tuesday. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80, Zacks reports. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 158.64%. The business had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million.

Tonix Pharmaceuticals Stock Performance

NASDAQ:TNXP opened at $0.14 on Friday. Tonix Pharmaceuticals has a fifty-two week low of $0.12 and a fifty-two week high of $22.14. The firm’s 50 day moving average is $0.15 and its two-hundred day moving average is $1.48. The company has a quick ratio of 0.72, a current ratio of 1.15 and a debt-to-equity ratio of 0.13.

Wall Street Analyst Weigh In

TNXP has been the topic of several recent analyst reports. Alliance Global Partners upped their target price on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd. StockNews.com assumed coverage on Tonix Pharmaceuticals in a research note on Wednesday. They issued a “sell” rating for the company.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.